Merck Says the Time to Raise Money Is Now—$137 Decides Whether the Record Run Resumes

Merck closed up 0.65% at $144.87, holding the day's gap, after executives said the timing is favorable for raising fresh capital—from a stock that just touched all-time highs.

Merck is one of the oddest things in big pharma this year: a company being rewarded for the patent cliff everyone was afraid of. The shares spent much of 2025 near $78, priced like a mature drugmaker with one giant problem hanging over it. Then the market decided Keytruda's looming loss of exclusivity could actually be managed, and MRK has run roughly 37% since January to a record $156.92 in late August.

Now it is pulling back, and management chose the pullback to talk about money.

An exec opened the door to a raise. At the Morgan Stanley Global Healthcare Conference on September 14, with the stock near record highs, Merck's leadership flagged that the timing is right for raising capital. The meaning is subtle and easy to miss: a pharma giant rarely needs to sell stock, but it loves having the option. With the equity trading near its all-time high, Merck can raise money on its cheapest terms in years—dry powder it can aim at the deals that are supposed to replace Keytruda's revenue when the patents begin to expire in 2028.

That is the derisking story, restated in the language of the balance sheet. Merck has already gone to the debt market to fund the build-out, pricing $6 billion of senior notes in May, after spending $6.7 billion on Terns Pharmaceuticals and $9.2 billion on flu-drug maker Cidara. Leverage is climbing. The signal from today is that the equity side of the ledger is now in play too—cheaply, and on Merck's terms.

The chart says the rally hasn't broken yet. After making that record high in late August, MRK gave back about 8% into a five-day slide that left it down 3.6% on the week. But look at where it stopped. The stock closed Monday at $144.87 after opening with a gap from Wednesday's $143.93 close, and it defended that gap into the bell rather than filling it. The 50-day line sits at $136.35, a full six points below Monday's close; the 200-day is at roughly $120. In plain terms, the pullback has so far been a pause inside an uptrend, not the end of one.

The participation on Monday actually tilted institutional. Block orders showed $52 million flowing in against $31 million flowing out, while retail traders were modest net sellers. That is the profile of patient money stepping in on the dip while the crowd chases—the same "who is trapped" dynamic that can turn a retest into the next leg.

The level that reorganizes the trade is $137. Use the 50-day as the fence, not a round number. If MRK reclaims the upper part of Monday's range—say a close back above $147, this month's swing high—the pullback looks like a coil and the path reopens toward retesting $156.92, then the fresh ground implied by Morgan Stanley's upgrade to a $179 target. A reclaim also puts the post-record breakout buyers back in profit, and trapped sellers who shorted the fade become fuel.

If instead MRK loses $137 and the gap zone beneath it, the structure changes. The stock would be back below where it launched its run, the 50-day would flip from support to ceiling, and the record-high zone from $147 to $157 becomes overhead supply full of underwater buyers. Below that, the chart does not offer much real structure until the mid-$120s.

Scenario	Trigger	Path	Invalidation	Horizon
Rally resumes	Close above $147	Retest record $156.92, then $170s	Daily close under $144	Days to weeks
Coil holds	Hold $144–145 gap, base	Reclaim $147, break $157	Losing $144	Days
Breakdown	Close under $137 (50-day)	Air pocket to mid-$120s	Weekly close back over $137	Days

Two things keep this honest. First, the raise itself cuts both ways. Equity issuance at record highs is cheap for Merck, but it is dilutive for holders and a reminder that the Keytruda-replacement program still costs billions with no guarantee of blockbuster output. That is exactly the concern behind RBC's downgrade even as Morgan Stanley turned more bullish—the market has already marked this optimism up, and the bar for the pipeline to clear is high. Second, Monday's constructive close is one session, not a trend; the setup has until it can put a firm close above $147 to prove the buyers are real.

The verdict is a binary any reader can check on the next tape: hold $137 and the record-run rally stays in play; lose it and the trap springs shut on the breakout crowd, with the pullback turning from pause into decline.